Whither CAR T? will the FDA being under the hood and the availability of bispecifics make these therapies less attractive?

IF 2.5 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

American Journal of Managed Care Pub Date : 2024-06-01 DOI:10.37765/ajmc.2024.89576

Sang Chao, Justin Tse, Amy VanGalder, Garrick Wong, Terra Wonsettler, Andrew Hertler

引用次数: 0

查看原文本刊更多论文

FDA 的介入以及双特异性药物的出现是否会降低 CAR T 疗法的吸引力？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Managed Care 医学-卫生保健

CiteScore

3.60

自引率

0.00%

发文量

177

审稿时长

4-8 weeks

期刊介绍： The American Journal of Managed Care is an independent, peer-reviewed publication dedicated to disseminating clinical information to managed care physicians, clinical decision makers, and other healthcare professionals. Its aim is to stimulate scientific communication in the ever-evolving field of managed care. The American Journal of Managed Care addresses a broad range of issues relevant to clinical decision making in a cost-constrained environment and examines the impact of clinical, management, and policy interventions and programs on healthcare and economic outcomes.